Competitor Analysis: Antihypertensives

The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension and intradialytic hypertension. The report also provides information about the market size of the largest drug class for treatment of arterial hypertension, i.e. angiotensin receptor blockers. Among the companies active in the field of new antihypertensives are Sanofi-Aventis, Daiichi-Sankyo, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Pfizer, Bayer Schering Pharma, Eli Lilly, Takeda Pharmaceuticals, Novartis and many others. The report includes a compilation of current active projects in research and development of novel antihypertensives. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Additional Information

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.